Latest News for: exons

Edit

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

PR Newswire 17 Mar 2025
Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal and cardiac muscle tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin.
Edit

Investor Alert (Exons Group) (CSA - Canadian Securities Administrators)

Public Technologies 03 Mar 2025
) Exons Group. Name Exons Group ... Supporting Documents Exons Group[English]. Note Exons group is not registered with the ... Last website(s) used exonsgrp.com, exons-grp.com.
  • 1
×